Fig. 3

LBPs suppress YAP1-overexpression-driven malignant progression of breast cancer cells. (A) RT-qPCR analysis of the relative mRNA expression of YAP1 in MDA-MB-231 cells after transfection with YAP1-siRNA. Data are presented as the mean ± SD (n = 3), *** P < 0.001, ** P < 0.01. (B,C) Colony formation assays were used to evaluate the proliferative capacity of MDA-MB-231 cells after LBPs treatment or transfection with a YAP1-overexpression plasmid or YAP1-siRNA. Data are presented as the mean ± SD (n = 3), *** P < 0.001. ns: not significant. (D,E) Representative TUNEL staining images of MDA-MB-231 cells after LBPs treatment, transfection with the YAP1-overexpression plasmid, or YAP1-siRNA. Red fluorescence indicates TUNEL-positive cells and blue fluorescence denotes nuclei. Data are presented as the mean ± SD (n = 3), *** P < 0.001, ** P < 0.01, ns: not significant. Scale bar, 200 μm. (F,G) Actin-Tracker Green-488 probes were employed to visualize F-actin architecture in MDA-MB-231 cells after LBPs treatment, transfection with the YAP1-overexpression plasmid, or YAP1-siRNA. Data are presented as the mean ± SD (n = 3), *** P < 0.001. ns: not significant. Scale bar, 50 μm. (H,I) Transwell assays were performed to evaluate the invasive capacity of MDA-MB-231 cells after LBPs treatment, transfection with the YAP1-overexpression plasmid, or YAP1-siRNA. Data are presented as the mean ± SD (n = 3), *** P < 0.001, ** P < 0.01, ns: not significant. Scale bar, 200 μm.